News

Press Releases

Dec 21, 2011
Repligen Announces Submission of New Drug Application for SecreFlo™ for Improved Pancreatic Imaging In Patients with Pancreatitis
Dec 20, 2011
Repligen Completes Acquisition of Novozymes Biopharma Sweden AB
Oct 27, 2011
Repligen Acquires Business of Novozymes Biopharma Sweden AB
Oct 27, 2011
Repligen Reports Second Quarter Fiscal Year 2012 Financial Results
Oct 26, 2011
Repligen Announces Conference Call of Second Quarter Fiscal Year 2012 Results
Oct 04, 2011
Repligen Provides Q2 FY2012 Corporate Update Regulatory Progress on SecreFlo™ and Record Sales of Bioprocessing Products
Aug 31, 2011
Repligen to Present at Upcoming Investor Conferences
Aug 11, 2011
Repligen Announces Robert A. Spurr Joins Company as Senior Vice President of Sales and Marketing and Chief Commercial Officer
Jul 27, 2011
Repligen Reports First Quarter Fiscal Year 2012 Financial Results
Jul 21, 2011
Repligen Announces Initiation of RG1068 Pilot Study to Improve Identification and Characterization of Pancreatic Cancer
Jul 20, 2011
Repligen Announces Conference Call of First Quarter Fiscal Year 2012 Results
Jul 15, 2011
Karen A. Dawes Elected as Repligen Co-chairperson of the Board of Directors
Jun 23, 2011
Repligen Receives U.S. Fast Track Designation and European Orphan Medicinal Product Recommendation for RG3039 for Spinal Muscular Atrophy
Jun 09, 2011
Repligen Reports Fourth Quarter and Fiscal Year 2011 Financial Results and Updates Expectations and Corporate Goals for Fiscal Year 2012
Jun 07, 2011
Repligen Announces Conference Call to Discuss Fiscal Year 2011 Financial Results and Update Fiscal Year 2012 Financial Expectations and Corporate Strategy Thursday June 9, 10:00 a.m. EDT
Jun 01, 2011
Repligen Concludes Pre-NDA Meeting with FDA for RG1068 Company Intends to File NDA for Pancreatic Imaging
May 19, 2011
Repligen Receives FDA Approval to Initiate Phase 1 Clinical Trial of Potential Treatment for Spinal Muscular Atrophy
Apr 21, 2011
Repligen Reports Preliminary Fiscal Year 2011 Financial Results and Financial Guidance and Development Goals for Fiscal Year 2012
Apr 15, 2011
Repligen Announces Conference Call to Discuss Preliminary Fiscal Year 2011 Financial Results and Fiscal Year 2012 Corporate Goals and Financial Expectations
Apr 08, 2011
Repligen to Present at the Biocentury and Thomson Reuters 18th Annual Future Leaders in the Biotech Industry Conference